We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | NASDAQ:AMGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.67 | -0.53% | 313.05 | 313.05 | 316.90 | 315.28 | 310.37 | 315.01 | 1,974,223 | 01:00:00 |
From May 2019 to May 2024
By Carlo Martuscelli
AstraZeneca PLC (AZN.LN) said Friday that its tezepelumab drug, which it is developing with Amgen Inc. (AMGN), was granted breakthrough therapy designation by the U.S. Food and Drug Administration.
The FDA awarded the designation to tezepelumab for treatment of patients with severe asthma--without an eosinophilic phenotype--who are receiving inhaled steroids or long-acting beta2-agonists.
The designation allows a treatments for severe conditions to pass through development and regulatory review more quickly, and is granted when there are clinical results that suggest it is substantially more effective than other medicine.
AstraZeneca said that the breakthrough therapy designation was given based on the results of the Pathway phase 2 study that showed a significant reduction in asthma exacerbation rate in a broad population of patients.
Write to Carlo Martuscelli at carlo.martuscelli@dowjones.com
(END) Dow Jones Newswires
September 07, 2018 02:33 ET (06:33 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
